Table 1.

Published studies of once-weekly versus twice-weekly bortezomib.

Reference	Overall response rate		Median PFS (95% CI), months
	Once-weekly	Twice-weekly	Once-weekly	Twice-weekly
Sidana et al. [6]a	76.6%	71.4%	NR	NR
Mateos et al. [7]	71.2%	76.1%	19.1 (17.8–21.6)	19.6 (18.8–21.0)
Cook et al. [8]b	73.0%	66.0%	36.2 (NR)	38.9 (NR)

Overall response rates and median progression-free survival are depicted for analysis. When multiple regimens or dosing routes were included, unadjusted comparisons with subcutaneous dosing of once-weekly versus twice-weekly bortezomib (assuming 21-day cycles) are shown.

CI confidence interval, NR not reported, PFS progression-free survival.

^aIncluded patients with AL amyloidosis.

^bVery good partial response or better.